Early, Final Effects of SAD Tx Unrelated (CME/CE)
By John Gever, Senior Editor, MedPage Today
PHILADELPHIA — Early responses to light therapy for seasonal affective disorder (SAD) do not necessarily predict how patients will ultimately do on the treatment, a researcher stated here.
In a placebo-controlled, crossover study of 79 patients with SAD, the correlation coefficient for outcomes after 1 hour compared with outcomes after 6 weeks was close to zero, stated Monika Acharya, MD, of Baltimore University in Baltimore.
The lack of correlation came despite substantial declines in average symptom scores from baseline both after the first session and at the end of the 6-week course of treatment, she reported at the American Psychiatric Association’s annual meeting.
For many medical conditions, early responses are predictive of medium- to long-term outcomes. In the case of light therapy for SAD, biological changes are detectable immediately, Acharya explained, which would suggest that the initial response could be used to identify patients who would benefit from continued therapy versus those who should be switched to alternative treatments.
She noted that previous studies had found that almost half of SAD patients do not respond to light therapy.
The current study included 79 patients, about two-thirds female, with a mean age of 44. They qualified for a SAD diagnosis on the basis of structured clinical interviews and were not taking psychotropic medications.
Patients were randomized to an initial 2-hour session of bright white light or red light, the latter serving as placebo. Subsequently, all patients then received 6 weeks of daily, 1-hour treatment with white light in the morning.
After the first week, patients talked by phone with clinic staff each week about their responses, including side effects. The duration and timing of treatment could then be adjusted, Acharya said.
Depression symptoms were evaluated primarily with the SIGH-SAD instrument, a SAD-specific form of the Hamilton Depression Rating Scale. All patients had scores higher than 20 at baseline with a mean of 32.3.
The first treatment led to small reductions in SIGH-SAD scores in both the white- and red-light groups: 1.6 points with white light (P=0.03) and 0.8 points with red light (P=0.20).
After 4 weeks, mean scores had dropped to 12.7, and by week six they had declined further to an average of 8.3. Some 63% of patients were responders and 31% had symptoms resolved by week 4; after another 2 weeks of treatment, 82.1% had responded and 58% were in remission.
But responses after 1 hour and after 6 weeks were not correlated at all, Acharya reported, irrespective of whether they were assigned to red or white light at the first session.
Nor was a 20% reduction in SIGH-SAD scores after the first session — seen in nine participants — significantly associated with remission at 4 or 6 weeks.
On the other hand, she and her colleagues found that body mass index did correlate significantly with response, such that patients with a higher BMI had greater responses to the light therapy.
Acharya told MedPage Today that the flexible dosing granted in the study was a significant limitation. She did not have data on whether there was a relation between outcomes after the first session or at later evaluations and patients’ dosing patterns during the trial.
No external funding for the study was reported.
Acharya stated she had no relevant financial interests.
Primary source: American Psychiatric Association Source reference: Acharya M, et al “Early response to bright light and outcome at six weeks” APA 2012; Abstract NR1-51.
Related News:
- AHA: HDL Boosters Still Promising (CME/CE)
- AHA: Chelation Tx in Post-MI Not Ready Yet (CME/CE)
- Novel Drug Helps Statins Cut Cholesterol (CME/CE)
- Psoriasis Drug Eases Refractory Crohn’s Disease (CME/CE)
- Mom’s Depression Slows Baby’s Development (CME/CE)
- Genes Point to Risk of Finger Disease (CME/CE)
- CJD Dementia Diagnosis Often Delayed (CME/CE)
- CJD Dementia Diagnosis Often Delayed (CME/CE)
- DNA Not Enough to Target HPV as Cancer Culprit (CME/CE)
- DNA Not Enough to Target HPV as Cancer Culprit (CME/CE)
Details :
Submited at Sunday, May 6th, 2012 at 3:00 am on Uncategorized by jessica
Comment RSS 2.0 - leave a comment - trackback


